Innova Captab Reports Strong FY26 Growth

Innova Captab's revenue from operations surged 31.1% to ₹1,630.02 crore in FY 2026, up from ₹1,243.68 crore in FY 2025. The company's EBITDA rose 26.3% to ₹250.34 crore, maintaining a 15.4% margin.

Reader Takeaway: Strong revenue growth and new facility operationalization, but monitor standalone profit impact.

What just happened

Innova Captab Limited announced its financial results for Fiscal Year 2026. Consolidated revenue from operations reached ₹1,630.02 crore, an increase of 31.1% year-on-year. Consolidated EBITDA grew by 26.3% to ₹250.34 crore, while Profit After Tax (PAT) saw a 9.9% rise to ₹140.92 crore. The company successfully commissioned its new manufacturing facility in Kathua, Jammu, in January 2025.

Why this matters

The significant revenue growth indicates strong market demand for Innova Captab's CDMO services and Branded Generics. The new facility is poised to offer future growth and operational leverage, supported by government incentives. However, investors will watch the impact of scaling costs on the company's standalone profitability.

The backstory

Innova Captab operates in the pharmaceutical sector, focusing on contract development and manufacturing (CDMO) services and branded generics. The company has been expanding its manufacturing capabilities to meet growing demand and diversify its geographical presence, with exports contributing over 31% of revenue.

What changes now

With the Kathua facility now operational, Innova Captab has enhanced its production capacity. This expansion is expected to drive future revenue and profitability through operating leverage. The company also declared an interim dividend of ₹2 per equity share.

Risks to watch

While consolidated performance is robust, standalone PAT saw a slight decrease. The costs associated with scaling up the new Jammu facility could impact short-term profitability. The company is also exposed to general industry risks like volatile commodity prices and currency fluctuations.

Peer comparison

(No specific peer comparison data available in the filing)

Context metrics (time-bound)

Consolidated Revenue: ₹1,630.02 crore (FY26) vs ₹1,243.68 crore (FY25), +31.1% YoY.
Consolidated EBITDA: ₹250.34 crore (FY26) vs ₹198.20 crore (FY25), +26.3% YoY.
Consolidated PAT: ₹140.92 crore (FY26) vs ₹128.26 crore (FY25), +9.9% YoY.
EBITDA Margin: 15.4% (FY26 & FY25).
Standalone PAT: ₹836.92 million (FY26) vs ₹894.70 million (FY25), -6.46% YoY.

What to track next

Investors should closely monitor the capacity utilization and revenue contribution of the new Kathua facility. The company's ability to translate this capacity into improved standalone and consolidated profitability will be key.